Added to YB: 2025-09-11
Pitch date: 2025-07-16
ATRC [bullish]
AtriCure, Inc.
+39.41%
current return
Author Info
No bio for this author
Company Info
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Market Cap
$1.8B
Pitch Price
$30.40
Price Target
N/A
Dividend
N/A
EV/EBITDA
-142.66
P/E
-46.87
EV/Sales
3.50
Sector
Health Care Equipment and Supplies
Category
growth
Riverwater Partners Small Cap Strategy New Position: AtriCure, Inc.
ATRC (new position): Leading AFib treatment innovator expects 14-16% annual revenue growth, cash flow positive going forward. Stock sold off in 2024 as new pulse-field ablation procedures diverted cardiology attention from surgical ablation/LAAM. EU precedent shows AFib market returns post-PFA adoption. Well-positioned for 2025 growth resumption.
Read full article (1 min)